Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.
Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209–25.
Cortese S, D’Acunto G, Konofal E, et al. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2017;31(2):149–60.
Mattingly GW, Wilson J, Rostain AL. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657–66.
Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII: US prescribing information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.
Prince J. Catecholamine dysfunction in attention-deficit/ hyperactivity disorder: an update. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S39–45.
Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008;28(3 Suppl 2):S54–61.
Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S46–53.
Quinn D. Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S62–6.
Markowitz JS, DeVane CL, Pestreich LK, et al. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006;16(6):687–98.
Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997;131(1):71–8.
Childress A, Newcorn J, Stark JG, et al. A single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26(6):505–12.
Weisler RH, Stark JG, Sikes C. Fed and fasted administration of a novel extended-release methylphenidate orally disintegrating tablet formulation for the treatment of ADHD. Clin Pharmacol Drug Develop. 2017. https://doi.org/10.1002/cpdd.361.2017 (Epub).
Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.
Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43(6):1084–95.
Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.